Medical Condition News

RSS

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

Astronomers to develop potential new cancer radiation treatment

Astronomers' research on celestial bodies may have an impact on the human body. Ohio State University astronomers are working with medical physicists and radiation oncologists to develop a potential new radiation treatment - one that is intended to be tougher on tumors, but gentler on healthy tissue.

27 Jun 2011

23andMe study discovers two novel gentic associations with Parkinson's

Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.

27 Jun 2011

McMaster researchers to use tiny worms for Parkinson's project

McMaster researchers from three disciplines are deploying thousands of tiny worms and a homegrown invention to test drugs in a collaborative bid to defeat Parkinson's Disease.

27 Jun 2011

Young adults with juvenile diabetes may face risk of heart attack and stroke

New research shows that adolescents and young adults with type 1 (juvenile) diabetes have thicker and stiffer carotid arteries, also known as atherosclerosis, a risk factor for heart attack and stroke in adults.

27 Jun 2011

Cardiac arrest represents tremendous problem for hospitals in the U.S.

More than 200,000 people are treated for cardiac arrest in United States hospitals each year, a rate that may be on the rise. The findings are reported online this week in Critical Care Medicine in a University of Pennsylvania Perelman School of Medicine-led study.

27 Jun 2011

Intravenous diclofenac holds promise against severe pain following oral surgery

An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.

27 Jun 2011

ACS to honor Brookhaven Lab's senior chemist for brain research

Joanna Fowler, a senior chemist and director of radiotracer chemistry, instrumentation, and biological imaging at the U.S. Department of Energy's Brookhaven National Laboratory, is one of 23 women from around the world who has been chosen to receive a Distinguished Women in Chemistry/Chemical Engineering Award, sponsored by the American Chemical Society (ACS).

27 Jun 2011

Some HIV drugs can cause premature ageing

A class of anti-retroviral drugs commonly used to treat HIV, particularly in Africa and low income countries, can cause premature ageing, according to research published today in the journal Nature Genetics. The study shows that the drugs damage DNA in the patient's mitochondria - the 'batteries' which power their cells.

27 Jun 2011

Diabetic patients can benefit from basal insulin analogs

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes.

27 Jun 2011

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

Data presented today from an analysis of samples from the European Diabetes Prevention Study (EDIPS) showed that the PreDx Diabetes Risk Score (DRS) is lowered by lifestyle intervention, which correlates to a reduction in the risk that patients will develop diabetes over time.

27 Jun 2011

Diabetes more prevalent in every part of the world

A major international study collating and analyzing worldwide data on diabetes since 1980 has found that the number of adults with the disease reached 347 million in 2008, more than double the number in 1980. The research, published today in The Lancet, reveals that the prevalence of diabetes has risen or at best remained unchanged in virtually every part of the world over the last three decades.

27 Jun 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

Why breakfast with a friend could be just what the doctor ordered

Spending too much time alone and regularly skipping breakfast might be pushing you closer to heart disease, warns the National Heart Foundation of Australia.

26 Jun 2011

Isotechnika's partner Lux to appeal EMA CHMP decision against Luveniq

Isotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc. will appeal the European Medicines Agency's (EMA) decision not to approve Luveniq™ (voclosporin) as a treatment for noninfectious uveitis involving the intermediate or posterior segments of the eye.

24 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

Experts discuss global threat of Alzheimer's disease at House subcommittee hearing

"Alzheimer's experts urged U.S. lawmakers on Thursday to increase funding for research of the debilitating disease and to push international policymakers to pay more attention to its global impact," Reuters reports (Steenhuysen, 6/23).

24 Jun 2011

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.

24 Jun 2011